Advanced searches left 3/3

MMR Vaccine - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 11 November 2021

* If you want to update the article please login/register

Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers

Subjects of team A and B will get MV-CHIK reduced dose or control-vaccine Priorix ® and topics of group C and D will be treated with MV-CHIK high dose or control-vaccine. All subjects of group A, C, b and d additionally will be randomized to either treatment series: team A and C will obtain MV-CHIK or control-vaccine Priorix ® on research day 0 and 28, adhered to by sugar pill on day 196, and group B and D receive sugar pill on day 0 and MV-CHIK or Priorix ® on day 28, adhered to by an added vaccination of the very same item on day196. All subjects of the measles booster group M1 and M2 will receive five i. m. Group M2 will get sugar pill on day 0 and 28 and MV-CHIK on day 168 and on day 196.

Source link: https://clinicaltrials.gov/ct2/show/NCT02861586

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions